Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities... BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. Mehr anzeigen
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company developing innovative...
FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company developing innovative...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1257 | -7.15953750641 | 1.7557 | 1.7557 | 1.5601 | 21285 | 1.61875376 | CS |
| 4 | -0.1391 | -7.8627550732 | 1.7691 | 1.8556 | 1.43 | 34005 | 1.62266675 | CS |
| 12 | -0.8 | -32.9218106996 | 2.43 | 2.53 | 1.43 | 24878 | 1.79930465 | CS |
| 26 | -0.71 | -30.3418803419 | 2.34 | 2.6 | 1.43 | 25275 | 1.99315352 | CS |
| 52 | 0.73 | 81.1111111111 | 0.9 | 4 | 0.7777 | 81921 | 2.56073455 | CS |
| 156 | -2.98 | -64.6420824295 | 4.61 | 5.175 | 0.542 | 228472 | 2.1532443 | CS |
| 260 | -13.79 | -89.4293125811 | 15.42 | 33 | 0.542 | 456138 | 13.14811705 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
